PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Jun 2012
At a glance
- Drugs Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Acronyms REVIR
- 11 Dec 2011 Status changed from recruiting to active, no longer recruiting. Overall, 37 patients were recruited and 10 months follow-up completed.
- 11 Dec 2011 Results were reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
- 29 Jul 2011 New trial record